Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

PURPOSE: The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The primary analysis of the Adjuvant Paclitaxel and Trastuzumab trial demonstrated a 3-year disease-free survival (D...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Tolaney, Sara M., Guo, Hao, Pernas, Sonia, Barry, William T., Dillon, Deborah A., Ritterhouse, Lauren, Schneider, Bryan P., Shen, Fei, Fuhrman, Kit, Baltay, Michele, Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Mathew J., Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth, Partridge, Ann H., Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2019
Aiheet:
RAPID COMMUNICATION
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587424/
https://ncbi.nlm.nih.gov/pubmed/30939096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00066
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia